Close

Australian COVID-19 vaccine shows promising results in animal trials

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Receptor Grade IGF-1 LR3: Expansive Research Potential

Receptor Grade IGF-1 LR3, an engineered analog of Insulin-like...

API China 2025 kicks off with Industry Buzz on Day One

At the China Import and Export Fair Complex in...

FDA Plans to Deploy AI Tools for Scientific Reviews

The US Food and Drug Administration has announced plans...

How To Select A CDMO: Focus On Client-Centered Approach

When it comes to the pharmaceutical sector, choosing the...

A COVID-19 vaccine candidate being developed by Australia’s University of Queensland has shown “positive” results against the novel coronavirus in preclinical tests, raising hopes for its potential effectiveness and manufacturability, the varsity said on Wednesday.

According to the yet-to-be published findings, the vaccine combined with the Seqirus MF59 adjuvant, provided protection against virus reproduction in hamster models, and reduced lung inflammation, following exposure to the virus.

Associate Professor Keith Chappell, who is the project co-leader, has reported to the International Society for Vaccines on the data from animal trials conducted by Viroclinics-DDL in the Netherlands, according to a statement.

“The neutralising immune response created by our molecular clamp vaccine in animal models was better than the average level of antibodies found in patients who have recovered from COVID-19,” Chappell said.

“It also induces a strong T-cell response and showed strong results when it came to data relating to manufacturability,” he said.

The researchers noted that one of the big challenges in the development of vaccines is the ability to produce them at sufficient scale for widespread use.

They said the phase 1 study being conducted in Queensland is progressing well and assuming the study demonstrates adequate safety and immune responses, data should be available in time to commence the required large-scale efficacy study before the end of the year.

Latest stories